Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus bevacizumab, improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events. (Funded by the Gruppo Oncologico Nord Ovest and others; ClinicalTrials.gov number, NCT00719797.).

Read Full Paperexternally

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Cite This Study

Loupakis et al. (Wed,) studied this question.

synapsesocial.com/papers/69d7bf43319e71454dbed866 https://doi.org/https://doi.org/10.1056/nejmoa1403108

Discussion

Journals

New England Journal of Medicine

Institutions

University of Padua

Sapienza University of Rome

Istituti di Ricovero e Cura a Carattere Scientifico

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.